Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists.

Slides:



Advertisements
Similar presentations
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
Advertisements

Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
SUDDEN DEATH IN VARIOUS POPULATIONS: IS GENDER A RISK FACTOR? 11 th International Symposium Heart Failure & Co Reggia di Caserta; April 29, 2011; 12:35.
Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.
La stratificazione del rischio aritmico oltre la frazione di eiezione Milano 17 Aprile 2009 Prof. Luigi Padeletti Heart Failure & Co.
Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate Medical Group Heart Failure and Pulmonary Arterial Hypertension.
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
חזק בהגנה לבבית Valsartan in Heart Failure
1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.
analysis from the SHIFT study
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) Echocardiographic.
Investigator Investigator: Sharma Kattel, MBBS Mentor: Mentor: Yuji Saito, MD, PhD, FACP, FACC Department of Internal Medicine Sisters of Charity Hospital.
Fonarow GC, et al. J Am Coll Cardiol. 2007;50:768  777. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Statins and Heart Failure
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
אי ספיקת לב ופרפור פרוזדורים - מגדר ד"ר א. שוטן מכון הלב הילל יפה, חדרה.
Sunil V. Rao MD The Duke Clinical Research Institute The Durham VA Medical Center Duke University Medical Center Transradial PCI in Octogenarians: Caveats,
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Presenter Disclosure Information Echocardiographic Tissue Doppler Imaging Is a Powerful Independent Prognosticator of Overall Mortality in the General.
Volume Status and Diuretic Therapy in Systolic Heart Failure, and the Detection of Early Abnormalities in Renal and Tubular Function Kevin Damman, Marie.
Association of C-Reactive Protein and Acute Myocardial Infarction in HIV-Infected Patients Virginia A. Triant, MD, MPH, James B. Meigs, MD, MPH, and Steven.
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
All Rights Reserved, Duke Medicine 2008 Mechanical Dyssynchrony Defined by Phase Analysis from GSPECT: Does It Predict Mortality? Paul L. Hess, MD; Linda.
Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Judith H. Veis, MD, FACP Associate Director, Nephrology
JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS
Revascularization in Patients With Left Ventricular Dysfunction:
Omar M Lattouf MD PHD FACC FACS
Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome Johanna E. Emmens, BSc, Jozine M. ter Maaten, MD, Yuya Matsue,
Recently Diagnosed vs Chronic HF Associated with Better Outcomes
Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
The percentage of subjects with de novo development of renal function impairment (GFR
Creatinine clearance (mL/min) n All-cause mortality (%)
Prevalence of statin and beta-blocker use by clinical presentation
Division of Cardiovascular Diseases No relevant author disclosures
TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Presentation transcript:

Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists Heart Failure and Pulmonary Arterial Hypertension Programs Medical Director, Edward Hospital Center for Advanced Heart Failure Naperville, Illinois, U.S.A.

Characteristics of Patients with Heart Failure and Normal or Reduced Ejection Fraction CharacteristicReduced EF (n=2429) Normal EF (n=2167) P Value Age (yr)71.7 ± ± 14.4< Male Sex (%) < BMI28.6 ± ± Obesity (%) sCr on adm. (mg/dl)1.6 ± Hgb on adm. (g/dl)12.5 ± ± 2.1< HTN (%) < CAD (%) < AF (%) < DM (%) Significant VHD (%)6.52.6<0.001 EF (%)29 ± 1061 ± 7<0.001 Owan TE et al. NEJM 2006; 355:251-9

Owan T et al. N Engl J Med 2006;355: Secular Trends in the Prevalence of Heart Failure with Normal Ejection Fraction

Secular Trends in Survival among Patients with Heart Failure and Normal or Reduced EF Owan T et al. NEJM 2006;355: Survival Improved Over Time in Patients with Reduced EF, But Not in Patients with Normal EF

Association of Clinical Characteristics with Mortality in Patients with Normal versus Reduced EF VariableNormal EFReduced EF AgeYES Female SexYES sCr on AdmissionYES Hgb on AdmissionYES HTNYES CADNOYES AFNO DMYES Significant VHDNO Year of AdmissionNOYES Owan T et al. NEJM 2006;355:

Jones, R.C. et al. J Am Coll Cardiol 2004;44: Predictors of Mortality in Patients with HF and Normal Systolic Function in the DIG Trial GFR NYHA III/IV Male gender Age Diuretics BMI CR Ratio DM Vasodilators K-Sparing Diur. DBP

Lee, D. S. et al. Circulation 2009;119: Survival of Patients with HFNEF and HFREF by Cause HFNEF HFREF

Tribouilloy C et al. EHJ 2008;29: Survival Curves by Etiology of HF with Normal EF

Impact of EF on Outcomes after PCI in HF Patients-NHLBI PTCA Registry Holper EM et al. AHJ 2006; 151: 69-75

Kaplan–Meier Analysis of the Probability of Survival among 3166 Patients with a Recent AMI Divided by No In-Hospital CHF, HFNEF (CHF+WMI>1.3), and HFREF (CHF+WMI<1.3), and Stratified According to Age. Møller J E et al. EJHF 2003;5:811-9 *No CHF vs. HFNEF p=  No CHF vs. HFREF p=

Prognostic Importance of Pulmonary Hypertension in Patients with HF Kjaergaard J et al. AJC 2007; 99:

Danciu Sc et al. AJC 2006; 97: 256-9

Racial Differences in the O utcomes of Patients with Diastolic HF CAD NO CAD white AA white AA P = P = East MA et al. AHJ 2004; 148: 151-6

Survival Kapoor JR et al. AHJ 2010; 159: 75-80

Anemia and Survival in Patients with Reduced and Normal EF Felker MG et al. AHJ 2006; 151:

Risk of Different Outcomes Associated with Diabetes in HFREF and HFNEF MacDonald M R et al. EHJ 2008;29:

Effect of Severe Autonomic Failure on Outcomes after MI in Patients with Normal LVEF Bauer A et al. EHJ 2009; 30: Severe autonomic failure (SAF): combination of severely impaired baroreflex function with abnormal autonomic tone, assessed by Heart Rate Turbulence (HRT) and cardiac Deceleration Capacity (DC).

BNP Predicts Medium-Term Risk in Patients with Acute HF and Normal EF BNP Levels Pg/mL P< 0.05 Valle R et al. JCF 2005; 11:

% P < P = P < P < Fonarow GC et al. JACC2007; 50:

Massie B et al. N Engl J Med 2008;359: Effects of Ibersartan in Patients with HFNEF

EF % of Patients * * * * * P = vs. prior year Massie BM et al. AJC 2007; 99:

Dobre D et al. EJHF 2007;9:280-6 VariableN (%)Adjusted HR 95% CIP value BB227(51) GFR ≤ 40 ml/min 247(56) COPD126(28) Male sex197(44) Digoxin98(22) VariableN(%)Adjusted HR 95% CiP value BB Low Dose93(41) BB High Dose134(59) Effect of Beta Blockers on Survival in Patients with Advanced HF and Normal EF

Conclusions The prevalence of HFNEF is increasing Hospitalizations for ADHF in patients with HFNEF are increasing The outcomes of HFNEF and HFREF are similar The outcomes of patients with HFNEF are determined by the presence and severity of comorbidities With the exception of BB, other therapies which improve the outcomes of patients with HFREF do not significantly alter morbidity and mortality of patients with HFNEF